Skip to main content
DIMERIX LIMITED logo

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Filings indexed 1,124 across all filing types
Latest filing 2014-09-17 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Replacement-Information Required Under Listing Rule 3.10.5A 1
Regulatory Filings
2014-09-17 English
Asthma Research Agreement & Capital Raising 2 pages 76.8KB
Regulatory Filings
2014-09-10 English
Investor Presentation 12 pages 804.1KB
Regulatory Filings
2014-09-10 English
Trading Halt 2 pages 122.4KB
Regulatory Filings
2014-09-09 English
Appendix 4E & Financial Statements 57 pages 2.2MB
Regulatory Filings
2014-08-24 English
Activity Report & Appendix 4C 6 pages 160.3KB
Regulatory Filings
2014-07-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.